[18F]DOPA PET 揭示胰腺神经内分泌肿瘤代谢活跃转录组状态与临床结局相关
该回顾性单中心研究基于74例原发胰腺神经内分泌肿瘤的转录组队列,其中22例有术前[18F]DOPA PET/CT,整合SUVmax与RNA测序数据。无监督聚类识别出两个分子亚型,cluster 1的[18F]DOPA摄取中位SUVmax为24.3,高于cluster 2的5.9(P=0.030),且与更晚期临床病理特征和更短无事件生存相关。SLC7A5表达在发现队列和全队列中均显著分层无事件生存,提示[18F]DOPA摄取可能无创反映肿瘤代谢活性。
要点
- cluster 1的[18F]DOPA摄取中位SUVmax为24.3,高于cluster 2的5.9(P=0.030)。
- 高摄取亚型富集细胞外基质、基质、血管和免疫相关成分及氨基酸转运和胺代谢基因。
- SLC7A5表达在发现队列和全队列中均显著分层无事件生存。
核心结论
- 胰腺神经内分泌肿瘤的[18F]DOPA PET摄取与氨基酸驱动的代谢程序(包括SLC7A5表达)及不良临床特征相关。
- 该摄取可能作为肿瘤代谢活性的无创读取指标,但作为影像生物标志物仍需独立验证。
研究设计与样本
- 回顾性单中心研究,基于74例原发胰腺神经内分泌肿瘤的转录组队列。
- 其中22例接受术前[18F]DOPA PET/CT的患者构成发现性放射转录组队列。
- 采用SUVmax量化肿瘤摄取,并与匹配的RNA测序数据整合。
- 进行无监督聚类、差异表达分析、基因集富集和肿瘤微环境解卷积。
- 在发现队列、全转录组队列(n=74)和独立外部队列(n=33)中评估SLC7A5的预后价值。
主要发现
- 无监督聚类识别出两个稳健的分子亚型:cluster 1和cluster 2。
- cluster 1的[18F]DOPA摄取中位SUVmax为24.3,高于cluster 2的5.9(P=0.030)。
- cluster 1与更晚期临床病理特征和更短无事件生存相关。
- cluster 1富集细胞外基质、基质、血管和免疫相关成分,并上调氨基酸转运和胺代谢基因(包括SLC7A5)。
- SLC7A5表达在发现队列中显著分层无事件生存,并在全队列中保持预后价值。
关键数值与推荐
- cluster 1与cluster 2的[18F]DOPA摄取中位SUVmax分别为24.3和5.9(P=0.030)。
- SLC7A5表达在发现队列和全队列(n=74)中显著分层无事件生存。
- 独立外部队列样本量为33例,用于评估SLC7A5的预后价值。
临床怎么用
- 对于胰腺神经内分泌肿瘤,术前[18F]DOPA PET/CT的高SUVmax可能提示氨基酸代谢活跃、侵袭性更强的转录组亚型。
- SLC7A5表达水平可作为预后分层参考,但需结合独立验证。
- [18F]DOPA PET摄取作为无创代谢读取指标的价值尚待独立验证后用于临床决策。
局限性
- 回顾性单中心设计。
- 发现性放射转录组队列样本量较小(22例)。
- 影像生物标志物的价值仍需独立验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[18F]fluorodihydroxyphenylalanine ([18F]DOPA) uptake is dependent on amino acid transport and decarboxylation pathways, including large neutral amino acid transporter 1, encoded by SLC7A5, which are linked to tumor aggressiveness. This study evaluated whether in vivo uptake of [18F]DOPA can serve as an imaging biomarker for pancreatic neuroendocrine tumors (panNETs), reflecting a tumor's transcriptional status and a patient's clinical course. Methods: This retrospective single-center study was based on a transcriptomic cohort of 74 primary panNETs. A subset of 22 panNETs from patients who underwent preoperative [18F]DOPA PET/CT constituted the discovery radiotranscriptomic cohort. [18F]DOPA tumor uptake was quantified using SUVmax and integrated with matched RNA-sequencing data. Unsupervised clustering, differential expression analysis, gene set enrichment, and tumor microenvironment deconvolution were performed to identify transcriptional programs associated with [18F]DOPA uptake. The prognostic value of SLC7A5 was evaluated in the discovery cohort, the full transcriptomic cohort (n = 74), and an independent external cohort (n = 33). Results: Unsupervised clustering of gene expression profiles identified 2 robust molecular subtypes: cluster 1 and cluster 2. Cluster 1 showed higher [18F]DOPA uptake than did cluster 2, with a median SUVmax of 24.3 versus 5.9, respectively (P = 0.030), and was associated with more advanced clinicopathologic features and shorter event-free survival. This subtype was also characterized by enrichment in extracellular matrix, stromal, vascular, and immune-related components, along with upregulation of amino acid transport and amine metabolism genes, including SLC7A5 As a mechanistic link between tracer uptake and tumor metabolism, SLC7A5 expression significantly stratified event-free survival in the discovery cohort and remained prognostic in the full cohort. Conclusion: [18F]DOPA PET uptake was associated with amino acid-driven metabolic programs in panNETs, including SLC7A5 expression, and adverse clinical features. These findings suggest that [18F]DOPA uptake may provide a noninvasive readout of tumor metabolic activity, although its value as an imaging biomarker requires independent validation.
引用
- Imperiale A, Lu X, Fattori A, et al. [18F]DOPA PET Reveals Metabolically Active Transcriptomic States Associated with Clinical Outcome in Pancreatic Neuroendocrine Tumors. J Nucl Med. 2026. PMID: 42914181. doi:10.2967/jnumed.126.273167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。